News
07-07-2010, 02:33 AM
Nektar Therapeutics announced today that data presented at the European Society for Medical Oncology (ESMO) 12th World Congress on Gastrointestinal Cancer demonstrates that NKTR-102, the company's lead oncology compound, exhibits superior activity compared to irinotecan as part of either a monotherapy or combination regimen in tumor models of gastrointestinal cancers.
More... (http://www.news-medical.net/news/20100707/Data-on-activity-of-Nektars-NKTR-102-in-gastrointestinal-cancer-presented-at-ESMO-12th-World-Congress.aspx)
More... (http://www.news-medical.net/news/20100707/Data-on-activity-of-Nektars-NKTR-102-in-gastrointestinal-cancer-presented-at-ESMO-12th-World-Congress.aspx)